Alexander Disease Clinical Study Treatment Trial
Ionis Pharmaceuticals announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder. Ionis today has announced that they have commenced a pivotal clinical study of ION373 – an investigational antisense medicine designed to reduce the level of GFAP – in patients with Alexander disease.